Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Inclusion Criteria: * Age ≥18 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Have metastatic or locally advanced mismatch repair deficient/MSI-H disease. * Patients must have received prior PD-1/PD-L1 inhibitor therapy * Patients with the presence of at least one measurable lesion. * Life expectancy of greater than 3 months. * Patients must have adequate organ and marrow function defined by study - specified laboratory tests. * Documented left ventricular ejection fraction (LVEF) ≥ 50% - 6 month prior to drug administration. * Must use acceptable form of birth control while on study. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Known history or evidence of brain metastases. * Require any antineoplastic therapy. * History of prior treatment with anti-LAG3. * Had chemotherapy, radiation, or steroids within 14 days prior to study treatment. * Had any investigational cytotoxic drug within 4 weeks prior to study treatment. * Have received any investigational drugs, a live vaccine, any allergen hyposensitization therapy, growth factors or major surgery within 28 days prior to study treatment. * Major surgery * Hypersensitivity reaction to any monoclonal antibody. * Has an active known or suspected autoimmune disease. * Has a diagnosis of immunodeficiency. * Prior tissue or organ allograft or allogeneic bone marrow transplantation. * Requires daily supplemental oxygen * History of inters…